Mon Sep 23 22:52:42 UTC 2024: ## Eli Lilly and Company Shares Dip Slightly, But Remain Positive Amidst Strong Analyst Sentiment

**New York, NY (MarketBeat News) -** Shares of pharmaceutical giant Eli Lilly and Company (LLY) experienced a minor dip on Monday, closing down 0.6% at $916.35. This comes despite a recent wave of positive analyst reports, which collectively paint a bullish picture for the company.

Trading volume for LLY on Monday was significantly lower than the average daily volume, suggesting a possible pause in investor activity. However, several brokerages have recently reiterated their confidence in the company.

Citigroup initiated coverage on LLY with a “buy” rating and a $1,060 price target. Bank of America boosted their price objective from $1,000 to $1,125, also maintaining a “buy” rating. JPMorgan Chase & Co. raised their target price from $1,050 to $1,100 while keeping an “overweight” rating. Deutsche Bank Aktiengesellschaft upgraded the stock from “hold” to “buy” and increased their target price from $725 to $1,025.

Overall, analysts have shown strong support for LLY, with 17 out of 20 analysts issuing “buy” ratings. This has resulted in a consensus rating of “Moderate Buy” and a consensus price target of $977.35.

Eli Lilly’s recent quarterly earnings also exceeded expectations, reporting $3.92 earnings per share and $11.30 billion in revenue. This strong performance fueled investor optimism.

While institutional investors have been actively trading LLY shares, with some increasing their holdings, insider selling has been observed in recent months. Notably, major shareholder Lilly Endowment Inc sold 1,441 shares in June, a transaction disclosed in an SEC filing.

Despite the minor dip in share price, Eli Lilly’s positive outlook remains intact, driven by strong earnings, favorable analyst sentiment, and continued development of its drug portfolio.

**Disclaimer:** This news article is for informational purposes only and should not be considered as investment advice.

Read More